Euroapi S.A. (OTCMKTS:EAPIF) Short Interest Update

Euroapi S.A. (OTCMKTS:EAPIF) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 46,171 shares, a growth of 110.6% from the December 31st total of 21,924 shares. Based on an average trading volume of 3 shares, the days-to-cover ratio is presently 15,390.3 days. Based on an average trading volume of 3 shares, the days-to-cover ratio is presently 15,390.3 days.

Euroapi Price Performance

Shares of OTCMKTS:EAPIF opened at C$2.53 on Friday. Euroapi has a 1 year low of C$2.46 and a 1 year high of C$3.74. The business’s 50-day moving average is C$2.97 and its 200-day moving average is C$3.20.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Euroapi in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Euroapi presently has a consensus rating of “Sell”.

About Euroapi

Euroapi is a standalone global active pharmaceutical ingredient (API) company formed in 2022 following its spin-off from the API division of a major multinational pharmaceutical group. The company focuses on the development, manufacturing and supply of a broad range of small-molecule APIs used in prescription drugs, over-the-counter products and vaccines. Its portfolio encompasses core areas such as semi-synthetic antibiotics (notably penicillins and cephalosporins), APIs for oncology, central nervous system disorders and cardiovascular therapies, as well as niche specialty ingredients.

Since its inception, Euroapi has pursued a growth strategy centered on innovation, capacity expansion and long-term partnerships with pharmaceutical customers.